TRU-015 for the Treatment of Rheumatoid Arthritis. According to Datamonitor, rheumatoid arthritis, or RA, is estimated to affect approximately 4.3 million people in the United States, Japan and Europe. Total reported worldwide sales of protein therapeutics used for the treatment of RA were $7.6 billion in 2005 and are expected to grow to $10 billion in 2010

EX-10.14 4 v18917a3exv10w14.txt EXHIBIT 10.14 EXHIBIT 10.14 LONZA AMENDMENT NO. 1 TO THE DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT dated 08 January 2004 between LONZA BIOLOGICS PLC and TRUBION PHARMACEUTICALS, INC. Re: Schedule 2 -- Services New Stage Add Stage 15 Development Pilot Batch (non-cGMP) at *** Scale Schedule 3 -- Price and Payment Price and Payment for Stage 15 CONFIDENTIAL TREATMENT LONZA THIS AMENDMENT is made the 4th day of June 2004 BETWEEN 1. LONZA BIOLOGICS PLC, the registered office of which is at 228 Bath Road, Slough, Berkshire SL1 4DX, England ("LB") and 2. TRUBION PHARMACEUTICALS, INC., of 2401 4th Avenue, Suite 1050, Seattle, WA 98121, USA (herein after referred to as the "Customer"). WHEREAS A. Customer and LB entered into a development and manufacturing services agreement dated 08 January 2004 ("the Agreement'), under which LB is required to perform Services relating to the Cell Line and the Product, as further described in the Agreement, and B. Customer would like LB to perform additional services under the Agreement, and C. LB is prepared to perform the additional services, and the parties wish to amend the Agreement accordingly. NOW THEREFORE it is agreed hereby as follows: 1. Schedule 2 of the Agreement shall be amended to include the following additional stage, Stage 15 (Development Pilot Batch (non-cGMP) at *** Scale): SCHEDULE 2 15 STAGE 15 -- Development Pilot Batch (non-cGMP) at *** Scale 15.1 OBJECTIVES *** 15.2 ACTIVITIES - ***. 15.3 TIMESCALE This Stage will commence any time after: - the *** is available for use, and/or; - sufficient information is available from Stages 1 and 3 of the Services to proceed. CONFIDENTIAL TREATMENT -2- LONZA This Stage shall be complete upon issue of the summary report to the Customer. It is estimated that this report shall be issued *** from commencement of this Stage. 2. Schedule 3 of the Agreement shall be amended by the addition of the following provisions in respect of the additional Stages contained in this Amendment No. 1: SCHEDULE 3 Price and Terms of Payment 1. Price In consideration for LB carrying out the Services described in Stage 15 as detailed in Schedule 2 the Customer shall pay LB as follows: STAGE *** Stage 15 Development Pilot Batch (non-cGMP) at *** Scale *** 2. Payment Payment by the Customer of the Price for Stage 15 shall be made against LB's invoices as follows: 2.1 For Stage 15 *** upon commencement of Stage 15. *** upon completion of Stage 15. 3. Any capitalized term used but not defined in this Amendment No. 1 shall have the meaning given in the Agreement. 4. Save as herein provided all other terms and conditions of the Agreement shall remain in full force and effect. CONFIDENTIAL TREATMENT -3- LONZA IN WITNESS WHEREOF the parties have caused this Amendment No. 1 to be executed by their duly authorised representatives thereunto as of the day and year first above written. Signed for and on behalf of LONZA BIOLOGICS PLC /s/ Rene Imwinkleried ---------------------------------------- Director TITLE Signed for and on behalf of TRUBION PHARMACEUTICALS, INC. /s/ Kendall Mohler ---------------------------------------- SVP, R&D TITLE CONFIDENTIAL TREATMENT -4-